Pneumococcal conjugate vaccine

The pneumococcal conjugate vaccine overcomes the poor immunogenicity of pure polysaccharide vaccines in young children by chemically coupling capsular polysaccharides to a carrier protein, such as CRM197 or tetanus toxoid. This conjugation converts the response from T-cell-independent to T-cell-dependent, enabling memory B-cell formation and booster responses.¹ The first PCV, PCV7, was licensed in 2000 and targeted the seven serotypes most common in pediatric invasive disease at the time. Subsequent formulations expanded coverage: PCV10 added serotypes 1, 5, and 7F; PCV13 added 3, 6A, and 19A; and newer PCV15 and PCV20 include additional serotypes like 22F and 33F.²

Introduction of PCV7 in the United States led to a >90% decline in invasive pneumococcal disease caused by vaccine serotypes in children under five, with substantial herd immunity in unvaccinated adults.³ However, serotype replacement—where non-vaccine serotypes increase—has partially offset gains, prompting the development of higher-valent vaccines. Globally, PCV introduction in low-income countries through Gavi has reduced childhood pneumonia mortality, though coverage gaps remain.⁴ The World Health Organization recommends PCV in all national immunization programs, with schedules of 2+1 or 3+0 doses.

Beyond the classic serotypes, PCVs have been used experimentally to combat antibiotic-resistant strains, and some studies suggest a role in reducing pneumococcal otitis media and sinusitis.⁵ The carrier protein CRM197, a non-toxic mutant of diphtheria toxin, is also used in other conjugate vaccines, such as Hib and meningococcal vaccines. In 2021, a 20-valent PCV (PCV20) was approved for adults, and PCV15 for children, reflecting ongoing serotype evolution. Notably, PCV does not cover serotype 3 effectively despite its inclusion, due to capsular shedding.⁶

PCVs have a favorable safety profile, with common adverse events being local reactions and mild fever. Severe allergic reactions are rare. In the United States, PCV15 and PCV20 are recommended for adults 65 and older, and for younger adults with risk conditions.² The WHO prequalification of PCV10 and PCV13 has facilitated global procurement, and ongoing research focuses on protein-based vaccines that could provide serotype-independent protection.⁴

Serotype

A distinct variation of a bacterial species based on its surface polysaccharides.

Herd immunity

Indirect protection of unvaccinated individuals due to reduced transmission in a vaccinated population.

CRM197

A non-toxic mutant of diphtheria toxin used as a carrier protein in conjugate vaccines.